Zydus, a leading, discovery-based, global pharmaceutical company announced that the US FDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of ...

The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb trial of its oral NLRP3 inflammasome inhibitor, Usnoflast, for ...

India's Zydus Lifesciences reported third-quarter profit above analysts' expectations on Wednesday, driven by strong demand for its generic drugs in its key U.S. market.

The shares of pharma major Cipla, Zydus Cadila, Jubilant Life Sciences and Dr Reddy Labs gained during the early trading hours on Friday after the US Food and Drug Administration (FDA) approved ...

The approval granted by the US Food and Drug Administration ... Ahmedabad. Zydus said Desidustat, sold under the Oxemia trademark, is a prescription drug approved in India for patients with ...

The company’s US formulations ... Zydus received FDA approval to conduct Phase II(b) clinical trials of Usnoflast for Amyotrophic Lateral Sclerosis (ALS), which has also received Orphan Drug ...

Shares of Zydus Lifesciences soared to a record ... of the company receiving tentative approval from the US Food and Drug Administration (FDA) for its Letermovir tablets. These tablets are crucial ...

helped by strong demand for generic drugs in its key United States and Indian markets. India's Zydus Life posts Q2 profit rise on steady US demand November 12, 2024 Indian generic drugmaker Lupin ...